Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482789 · ClinicalTrials.gov registry record · Phase 4
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
A Phase 4 study of Gestational Diabetes, sponsored by Maisa N. Feghali, MD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05482789 is a Phase 4 study of Gestational Diabetes that is actively recruiting participants, run by Maisa N. Feghali, MD. The registered enrollment target is 13 participants, below the 322-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05482789, a Phase 4 study of Gestational Diabetes, is actively recruiting participants, sponsored by Maisa N. Feghali, MD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.
Conditions Studied
Interventions
- DRUG Exenatide
Study Locations (1)
Pennsylvania
- Magee Womens Hospital of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05482789
The ClinicalTrials.gov registry entry for NCT05482789 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Maisa N. Feghali, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gestational Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Exenatide is the first listed.
NCT05482789 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05482789 about?
NCT05482789 is a clinical study titled "Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes". This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your ...
What is the current status of trial NCT05482789?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2023-04-12. Estimated completion is 2026-03-31.
What conditions does trial NCT05482789 study?
This clinical trial studies the following conditions: Gestational Diabetes.
What interventions are being tested in trial NCT05482789?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT05482789?
This trial is sponsored by Maisa N. Feghali, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482789 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GDM: Insulin with or Without Metformin?
RECRUITING · Phase 4
-
Gestational Diabetes and Pharmacotherapy (GAP)
RECRUITING · Phase 4
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
-
Delivering HOPE (Helping Women Optimize Prenatal Equity)
RECRUITING · NA
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.